← boardnext 2028-06-30
GERN
Geron Corporationdistress 4/10 · elevated risk$1.410%today-28% from 52w high
Lead: Myelofibrosis · est. market ~$4B (approx, global)
Revenue
$52M
Liquidity
$69M
Runway
0.6 yrs
Shares 1y
+1%
Price & events
-0.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.4%
1D
-1.1%
1W
+4.1%
1M
-6.3%
3M
+1.8%
6M
+5.6%
1Y
-69.6%
2Y
+8.9%
5Y
-13.8%
All
Overview
- Market Cap
- $901.34M
- Enterprise Value
- $952.27M
- Volume
- 464.66K
- 52 Week Range
- $1.07 – $1.95
- Total Shares
- 641.52M
- Float Shares
- 535.70M
- Short %
- 12.51%
- % Held by Insiders
- 0.08%
- % Held by Institutions
- 79.65%
- RVOL
- 0.04x
- Beta
- 0.60
Pipeline stages · 1 programs
Imetelstat, Best Available Therapy (BAT)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-06-30 Estimated 50% readout ~2028-09-13 | Phase 3 | Imetelstat, Best Available Therapy (BAT) | Myelofibrosis | — | active not recruiting |
Catalyst news & presentations · 2
- 2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
- 44th Annual J.P. Morgan Healthcare Conference week of January 12, 2026conferencedata presentationsecondaryCorporate presentation at JP Morgan conferenceSEC 8-K
Approved drugs (1)
- RYTELOIMETELSTAT SODIUM2024 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $3 (+142% upside) · 5 analysts
- 2025-11-05NeedhamBuy
- 2025-05-08ScotiabankSector Outperform → Sector Perform
- 2025-03-12NeedhamBuy
- 2025-03-12HC Wainwright & Co.Neutral
- 2025-02-27StifelBuy
- 2025-02-27ScotiabankSector Outperform
Competitors — Myelofibrosis
- MRKMerck & Co., Inc.$318.8B · D3
- NVSEFNOVARTIS AG$292.0B · D3
- GSKGSK plc$217.0B · D1
- TKPHFTAKEDA PHARMACEUTICAL CO LTD$53.7B · D1
- INCYINCYTE CORP$23.1B · D0
- IRONDisc Medicine, Inc.$2.8B · D1
- SNDXSyndax Pharmaceuticals Inc$1.9B · D5
- DMRADamora Therapeutics, Inc.$1.8B · D6
- PRLDPrelude Therapeutics Inc$307M · D6
- KPTIKaryopharm Therapeutics Inc.$157M · D7
Recent news
- 2026-07-22Five New Geron Hires Receive Options at $1.44 Per Share - Stock Titan
- 2026-07-22Geron Schedules 8 a.m. Q2 Conference Call for Aug. 5 - Stock Titan
- 2026-07-14Geron's New Business Chief Gets Option on 1.7M Shares - Stock Titan
- 2026-07-13Veteran dealmaker from Novartis and Cellworks joins Geron to steer RYTELO growth - Stock Titan
- 2026-06-18Geron dangles 690,000 options to recruit eight new employees - Stock Titan
- 2026-06-01Geron plans Goldman Sachs healthcare fireside chat, webcast June 8 - Stock Titan
- 2026-05-27Geron (NASDAQ: GERN) adds 4.5M shares to 2018 equity incentive plan - Stock Titan
- 2026-05-26Geron (NASDAQ: GERN) director awarded 220,000 options at $1.26 strike - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.